R-412

N/A

Report date: 2022/08/24 20:00:31
NME

Base Information

Drug NameR-412
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRegulatory T-lymphocytes modulators
TargetsUpdating
Therapy Area/IndicationsDiabetes Mellitus, Type 1Multiple SclerosisPulmonary Fibrosis +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRadikal Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRadikal Therapeutics
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 1Multiple SclerosisPulmonary Fibrosis +[5] 

Other Information

ATC CodeN/A
Related LinksN/A